on GENEURO SA (EPA:GNRO)
GeNeuro SA: Judicial recovery for its French subsidiary
Biopharmaceutical company GeNeuro SA has announced the opening of receivership proceedings for its French subsidiary, GeNeuro Innovation SAS, following a decision by the Lyon Economic Activities Court. Facing financial difficulties, the subsidiary sought this legal protection. The court appointed SELARL FHBX as receiver.
This restructuring is part of a broader restructuring of the group. On May 27, GeNeuro SA obtained a definitive stay of insolvency proceedings in Switzerland, with no direct impact from the restructuring of its subsidiary. Based in Geneva, GeNeuro focuses on developing treatments for neurodegenerative and autoimmune diseases.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENEURO SA news